Gene expression profiling of patient‐derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ 1: implications for individualized …

B Bian, M Bigonnet, O Gayet, C Loncle… - EMBO molecular …, 2017 - embopress.org
Abstract c‐MYC controls more than 15% of genes responsible for proliferation,
differentiation, and cellular metabolism in pancreatic as well as other cancers making this …

Pancreatic cancer organoids for determining sensitivity to bromodomain and extra-terminal inhibitors (BETi)

B Bian, NA Juiz, O Gayet, M Bigonnet… - Frontiers in …, 2019 - frontiersin.org
Pancreatic ductal adenocarcinoma (PDAC) is a heterogeneous disease, therefore
stratification of patients is essential to predict their responses to therapies and to choose the …

[HTML][HTML] Endogenous CHRNA7-ligand SLURP1 as a potential tumor suppressor and anti-nicotinic factor in pancreatic cancer

VM Throm, D Männle, T Giese, AS Bauer, MM Gaida… - Oncotarget, 2018 - ncbi.nlm.nih.gov
Smoking is associated with increased risk and poorer prognosis of pancreatic ductal
adenocarcinoma (PDAC). Nicotine acts through cholinergic nicotinic receptors, preferentially …

Human Retrotransposons and the Global Shutdown of Homeostatic Innate Immunity by Oncolytic Parvovirus H-1PV in Pancreatic Cancer

M Neulinger-Muñoz, D Schaack, SP Grekova… - Viruses, 2021 - mdpi.com
Although the oncolytic parvovirus H-1PV has entered clinical trials, predicting therapeutic
success remains challenging. We investigated whether the antiviral state in tumor cells …

Cytokine profiling of tumor-infiltrating T lymphocytes by flow cytometry

JB Foote, S Sarvesh, LA Emens - Methods in Enzymology, 2020 - Elsevier
Intracellular cytokine staining (ICS) utilizing fluorescently labeled, cytokine-specific
antibodies is a powerful technique utilized to evaluate cytokine expression that provides …